BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 1362093)

  • 1. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
    Rathbun RC; Martin ES
    Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).
    Moyle GJ; Nelson MR; Hawkins D; Gazzard BG
    Q J Med; 1993 Mar; 86(3):155-63. PubMed ID: 8387218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Didanosine.
    Shelton MJ; O'Donnell AM; Morse GD
    Ann Pharmacother; 1992 May; 26(5):660-70. PubMed ID: 1350471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Didanosine: long-term follow-up of patients in a phase 1 study.
    Lambert JS; Seidlin M; Valentine FT; Reichman RC; Dolin R
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S40-5. PubMed ID: 8093846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
    Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
    Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
    N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
    Valentine FT; Seidlin M; Hochster H; Laverty M
    Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.
    Dolin R; Lambert JS; Morse GD; Reichman RC; Plank CS; Reid J; Knupp C; McLaren C; Pettinelli C
    Rev Infect Dis; 1990; 12 Suppl 5():S540-9; discussion S549-51. PubMed ID: 1974726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
    Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
    Yarchoan R; Pluda JM; Thomas RV; Mitsuya H; Brouwers P; Wyvill KM; Hartman N; Johns DG; Broder S
    Lancet; 1990 Sep; 336(8714):526-9. PubMed ID: 1975038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
    Reddy MM; McKinley GF; Grieco MH
    J Clin Lab Anal; 1991; 5(6):396-8. PubMed ID: 1774603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
    Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
    Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
    Montaner JS; Rachlis A; Beaulieu R; Gill J; Schlech W; Phillips P; Auclair C; Boulerice F; Schindzielorz A; Smaldone L
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):924-30. PubMed ID: 7519674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
    Kelleher T; Cross A; Dunkle L
    Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
    Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J
    BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
    Nguyen BY; Shay LE; Wyvill KM; Pluda JM; Brawley O; Cohen RB; Whitcup SM; Venzon DJ; Broder S; Yarchoan R
    J Infect Dis; 1993 Oct; 168(4):810-7. PubMed ID: 8397267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.